

P-Cure Ltd Joins Prof. Josef Press To The Board Of Directors.

Tel Aviv, January 10, 2022 -- P-Cure Ltd., the provider of the most compact 360° gantry-less adaptive proton therapy system, announced today that Prof. Josef Press has joined its board of directors. This appointment has come into force following an equity investment in P-Cure by Medipress Health – Limited Partnership, headed by Prof. Press as a part of Series D investment round. Prof. Press is a former CEO of the only pediatric hospital in Israel and one of the top healthcare executives in the country.

“Investing in P-Cure is investing in the future of cancer care. It is a big deal for us as investors and as physicians, as today only P-Cure is realistically capable of providing access to the most targeted treatment of cancer with radiation,” says Prof. Press.

“The investment by Medipress is a clear validation of value we bring to our customers as perceived by healthcare providers. The appointment of Prof. Press will strengthen the company’s clinical leadership and boost our go to market strategy,” says Dr. Marash, the CEO of P-Cure.

Proton therapy is the most targeted radiation therapy for treatment of cancer patients due to its ability to precisely deposit the greatest amount of radiation onto a tumor while sparing nearby healthy tissues and organs. However, despite its clinical benefits and established reimbursement, the gigantic size and cost of current legacy technology prohibits integration of proton therapy into main clinical practice. Today, this technology and treatment is available to the patients in less than 1% of radiation therapy facilities throughout the world.

P-Cure has developed a compact proton therapy solution that eliminates the need for 80 to 100 ton gantries that have been an integral part of all legacy solutions. The company’s unique 360° gantry-less adaptive proton therapy system can be integrated into any radiation therapy department with significantly reduced capital and operating investment. By eliminating the economic barriers of proton therapy integration into common practice, P-Cure pursues a plan to become the number one provider of the most targeted radiation oncology solutions worldwide.

About Prof. Press:

Prof. Press is the CEO of Medipress Health – Limited Partnership and former CEO of Schneider Children’s Medical Center of Israel and Chairman of Pediatrics and Pediatric Emergency Medicine at Soroka University Medical Center. Prof. Press holds a professorship in the Sourasky faculty at Tel Aviv University Center and has filled a range of leadership positions at Ben Gurion University of the Negev. Prof. Press is an opinion leader in the fields of Pediatrics, Rheumatology, and Emerging Medicine having extensive research background with 80 peer review scientific publications. For the last several years, Prof. Press has been counselling several medical ventures and acting as a scientific advisory board member of numerous NASDAQ traded companies.

About P-Cure:

P-Cure Ltd is a developer and provider of the most compact proton therapy system that can be integrated in any radiation therapy departments and designed to improve clinical outcomes in treating all anatomic areas. The company’s headquarters are located in Israel with subsidiaries in the US and China. For more information please visit: www.p-cure.com